Amneal Pharmaceuticals, Inc. - News - Press Releases

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002

Sep 06, 2023

Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection

Sep 06, 2023

Amneal Receives First Product Approval in China

Sep 06, 2023

Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate

Aug 29, 2023

Delegation from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, and Local Government Officials Visit Amneal Manufacturing Site in India

Aug 25, 2023

Amneal to Participate at the 2023 Wells Fargo Healthcare Conference

Aug 24, 2023

JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease

Aug 04, 2023

Amneal Reports Second Quarter 2023 Financial Results

Jul 26, 2023

Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

Jul 06, 2023

Amneal to Report Second Quarter 2023 Results on August 4, 2023

Jul 03, 2023

Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

Jul 03, 2023

Amneal Receives U.S. FDA Complete Response Letter for IPX203

Jun 15, 2023

Amneal Releases 2022 Environmental, Social and Governance Report Mapped to the United Nations Sustainable Development Goals

Jun 14, 2023

Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable

May 24, 2023

Amneal to Participate at the 2023 Jefferies Healthcare Conference

May 16, 2023

Amneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United States

May 05, 2023

Amneal Reports First Quarter 2023 Financial Results

Apr 17, 2023

Amneal to Participate at the 22nd Annual Needham Virtual Healthcare Conference

Apr 17, 2023

Amneal Reports Certain Preliminary First Quarter 2023 Financial Results and Affirms Full Year 2023 Financial Guidance

Apr 12, 2023

Amneal to Report First Quarter 2023 Results on May 5, 2023

Mar 02, 2023

Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg

Mar 02, 2023

Amneal Reports Fourth Quarter and Full Year 2022 Financial Results

Jan 31, 2023

Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023

Jan 04, 2023

Amneal Announces Strategic European Partnership with Orion Corporation

© Amneal Pharmaceuticals LLC.

All rights reserved.

Powered By Q4 Inc. 5.104.0.1